186 related articles for article (PubMed ID: 19436291)
1. C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk.
Eklund CM; Tammela TL; Schleutker J; Hurme M
Br J Cancer; 2009 Jun; 100(12):1846-51. PubMed ID: 19436291
[TBL] [Abstract][Full Text] [Related]
2. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
Lehrer S; Diamond EJ; Mamkine B; Droller MJ; Stone NN; Stock RG
BJU Int; 2005 May; 95(7):961-2. PubMed ID: 15839913
[TBL] [Abstract][Full Text] [Related]
4. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels.
Cramer SD; Chang BL; Rao A; Hawkins GA; Zheng SL; Wade WN; Cooke RT; Thomas LN; Bleecker ER; Catalona WJ; Sterling DA; Meyers DA; Ohar J; Xu J
J Natl Cancer Inst; 2003 Jul; 95(14):1044-53. PubMed ID: 12865450
[TBL] [Abstract][Full Text] [Related]
5. Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancer.
Tajtakova M; Pidanicova A; Valansky L; Lachvac L; Nagy V; Sivonova M; Dobrota D; Kliment J; Petrovicova J
Neoplasma; 2010; 57(2):118-22. PubMed ID: 20099974
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism in the C-reactive protein (CRP) gene affects CRP levels in plasma and one early marker of atherosclerosis in men: The Health 2000 Survey.
Kettunen T; Eklund C; Kähönen M; Jula A; Päivä H; Lyytikäinen LP; Hurme M; Lehtimäki T
Scand J Clin Lab Invest; 2011 Sep; 71(5):353-61. PubMed ID: 21413847
[TBL] [Abstract][Full Text] [Related]
7. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
Wiklund F; Zheng SL; Sun J; Adami HO; Lilja H; Hsu FC; Stattin P; Adolfsson J; Cramer SD; Duggan D; Carpten JD; Chang BL; Isaacs WB; Grönberg H; Xu J
Prostate; 2009 Mar; 69(4):419-27. PubMed ID: 19116992
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Beer TM; Lalani AS; Lee S; Mori M; Eilers KM; Curd JG; Henner WD; Ryan CW; Venner P; Ruether JD; Chi KN;
Cancer; 2008 Jun; 112(11):2377-83. PubMed ID: 18428198
[TBL] [Abstract][Full Text] [Related]
9. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells.
Medeiros R; Morais A; Vasconcelos A; Costa S; Pinto D; Oliveira J; Carvalho R; Lopes C
Prostate; 2002 Sep; 53(1):88-94. PubMed ID: 12210484
[TBL] [Abstract][Full Text] [Related]
10. Kallikarein-related peptidase 3 common genetic variant and the risk of prostate cancer.
Motamedi RK; Sarhangi N; Afshari M; Sattari M; Jamaldini SH; Samzadeh M; Mohsen Ziaei SA; Pourmand GR; Hasanzad M
J Cell Biochem; 2019 Sep; 120(9):14822-14830. PubMed ID: 31017705
[TBL] [Abstract][Full Text] [Related]
11. Do preoperative serum C-reactive protein levels predict the definitive pathological stage in patients with clinically localized prostate cancer?
Schnoeller TJ; Steinestel J; Steinestel K; Jentzmik F; Schrader AJ
Int Urol Nephrol; 2015 May; 47(5):765-70. PubMed ID: 25787073
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation across C-reactive protein and risk of prostate cancer.
Markt SC; Rider JR; Penney KL; Schumacher FR; Epstein MM; Fall K; Sesso HD; Stampfer MJ; Mucci LA
Prostate; 2014 Jul; 74(10):1034-42. PubMed ID: 24844401
[TBL] [Abstract][Full Text] [Related]
13. Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study.
Johansson M; Holmström B; Hinchliffe SR; Bergh A; Stenman UH; Hallmans G; Wiklund F; Stattin P
Int J Cancer; 2012 Jan; 130(1):129-37. PubMed ID: 21328341
[TBL] [Abstract][Full Text] [Related]
14. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
Atkins KM; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
Cancer; 2018 Apr; 124(7):1383-1390. PubMed ID: 29266181
[TBL] [Abstract][Full Text] [Related]
15. Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer.
Cramer SD; Sun J; Zheng SL; Xu J; Peehl DM
Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2451-7. PubMed ID: 18768516
[TBL] [Abstract][Full Text] [Related]
16. Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels.
Jesser C; Mucci L; Farmer D; Moon C; Li H; Gaziano JM; Stampfer M; Ma J; Kantoff P
Br J Cancer; 2008 Nov; 99(10):1743-7. PubMed ID: 18827812
[TBL] [Abstract][Full Text] [Related]
17. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels.
Penney KL; Schumacher FR; Kraft P; Mucci LA; Sesso HD; Ma J; Niu Y; Cheong JK; Hunter DJ; Stampfer MJ; Hsu SI
Carcinogenesis; 2011 Jun; 32(6):853-9. PubMed ID: 21421545
[TBL] [Abstract][Full Text] [Related]
18. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?
Bantis A; Grammaticos P
Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
